We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+24.75%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$562M
AUM Growth
-$50.5M
Cap. Flow
-$95.7M
Cap. Flow %
-17.03%
Top 10 Hldgs %
67.51%
Holding
88
New
30
Increased
9
Reduced
14
Closed
29

Top Buys

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$12.1M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$6.11M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$5.66M
4
OBSV
ObsEva SA Ordinary Shares
OBSV
+$5.64M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$5.08M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$22.1M
2
ASND icon
Ascendis Pharma A/S
ASND
+$15.3M
3
GYRE icon
Gyre Therapeutics
GYRE
+$7.59M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$7.42M
5
ARWR icon
Arrowhead Research
ARWR
+$6.84M

Sector Composition

Rank Sector Weight
1 Healthcare 67.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CUTR
26
DELISTED
Cutera, Inc.
CUTR
$4.23M 0.75%
105,000
+35,000
+50% +$1.61M
XENE icon
27
Xenon Pharmaceuticals
XENE
$6.02B
$4.14M 0.74%
+450,000
New +$2.8M
AERI
28
PUT
DELISTED
Aerie Pharmaceuticals
AERI
$4.12M 0.73%
61,000
+51,000
+510% +$2.85M
APLS
29
DELISTED
Apellis Pharmaceuticals
APLS
$3.7M 0.66%
+168,000
New +$3.86M
ZGNX
30
CALL
DELISTED
Zogenix, Inc.
ZGNX
$3.65M 0.65%
+82,500
New +$3.4M
LITS
31
Lite Strategy Inc
LITS
$33.4M
$3.47M 0.62%
+44,004
New +$2.7M
ARWR icon
32
CALL
Arrowhead Research
ARWR
$12.1B
$2.72M 0.48%
+200,000
New +$1.87M
FENC icon
33
Fennec Pharmaceuticals
FENC
$333M
$2.61M 0.46%
250,000
– –
LRMR icon
34
Larimar Therapeutics
LRMR
$413M
$2.56M 0.46%
+20,833
New +$1.77M
IOVA icon
35
CALL
Iovance Biotherapeutics
IOVA
$1.93B
$2.43M 0.43%
190,000
-13,300
-7% -$194K
ACER
36
DELISTED
Acer Therapeutics Inc
ACER
$2.36M 0.42%
+109,270
New +$2.07M
DNTH icon
37
Dianthus Therapeutics
DNTH
$5.8B
$2.29M 0.41%
+10,625
New +$2.4M
TSRO
38
DELISTED
TESARO, Inc.
TSRO
$2.22M 0.4%
+50,000
New +$2.43M
BHVN
39
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.13M 0.38%
+53,800
New +$1.71M
ZGNX
40
PUT
DELISTED
Zogenix, Inc.
ZGNX
$1.99M 0.35%
+45,000
New +$1.85M
VCEL icon
41
Vericel Corp
VCEL
$2.36B
$1.84M 0.33%
+190,055
New +$2.37M
EDIT icon
42
CALL
Editas Medicine
EDIT
$407M
$1.79M 0.32%
+50,000
New +$1.77M
KZR
43
DELISTED
Kezar Life Sciences
KZR
$1.73M 0.31%
+10,000
New +$1.74M
DB icon
44
PUT
Deutsche Bank
DB
$69.8B
$1.59M 0.28%
+150,000
New +$1.91M
FTSV
45
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$1.17M 0.21%
+73,000
New +$1.13M
ESPR
46
PUT
DELISTED
Esperion Therapeutics
ESPR
$980K 0.17%
+25,000
New +$1.26M
AMAG
47
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
$975K 0.17%
50,000
– –
ALIM
48
DELISTED
Alimera Sciences
ALIM
$953K 0.17%
64,955
– –
OSUR icon
49
PUT
OraSure Technologies
OSUR
$286M
$824K 0.15%
50,000
– –
STAA icon
50
PUT
STAAR Surgical
STAA
$1.21B
$775K 0.14%
+25,000
New +$585K
1
2
3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2018 Portfolio in Review

As of Q2 2018, Acuta Capital Partners held 88 positions worth $562M, down 8.3% from $612M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Acuta Capital Partners withdrew a net $95.7M in Q2 2018, closing 29 positions and reducing 14 holdings. Its most notable exit was AveXis, Inc. Common Stock, an estimated $7.42M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 61% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in Madrigal Pharmaceuticals worth $9.73M.

  • Acuta Capital Partners's largest Q2 2018 buy was Madrigal Pharmaceuticals: 34,803 shares worth $9.73M.
  • Acuta Capital Partners added most to Kadmon Holdings, Inc. in Q2 2018, an estimated $12.1M increase.
  • Acuta Capital Partners's biggest Q2 2018 reduction was Immunomedics Inc, cutting an estimated $22.1M.
  • Acuta Capital Partners fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $7.42M.
  • Acuta Capital Partners's ten largest holdings make up 68% of its $562M portfolio in Q2 2018.
  • Acuta Capital Partners opened 30 new positions and closed 29 in Q2 2018.
  • Acuta Capital Partners's portfolio value fell 8.3% quarter-over-quarter to $562M.

Based on Acuta Capital Partners's 13F filing for Q2 2018, filed 15 Aug 2018.